Want to see ARCT full AI Analyst Report?
ARCT Stock Chart & Stats
$8.85
-$1.70(-8.19%)
At close: 4:00 PM EST
$8.85
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.85 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$206.92M
Enterprise Value$21.81M
Total Cash (Recent Filing)$211.38M
Total Debt (Recent Filing)$23.99M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 10, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding28,423,069
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.78
Price to Sales (P/S)2.50
P/FCF Ratio-2.26
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue0.48
Enterprise Value/Gross Profit0.53
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$20.00Price Target Upside125.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.03
Revenue Forecast (FY)$15.29M
Bulls Say, Bears Say
Bulls Say
Multi-year Cash RunwayA cash balance of $213.4M with management's stated runway beyond Q2 2028 materially lowers near-term financing risk. This durable liquidity position allows Arcturus to advance Phase 2/3 programs, pursue regulatory meetings and partner negotiations without immediate dilution or emergency financings, supporting program execution over the next 2–3 years.
Thermo Fisher Strategic PartnershipA strategic collaboration with Thermo Fisher creates integrated access to Phase 3 manufacturing, clinical research and commercial readiness. This durable operational backing reduces scale‑up, supply and regulatory execution risk for ARCT‑032, lowers capital intensity for Arcturus, and positions the company to meet late‑stage clinical and commercial product demands.
Proprietary LUNAR Delivery And Inhaled TolerabilityDemonstrated repeat inhaled dosing tolerability is a meaningful technical differentiation for inhaled mRNA. The proprietary LUNAR LNP chemistry and purification process that enabled month‑long unsupervised dosing address a core delivery challenge, improving the platform's long‑term viability for respiratory indications and strengthening Arcturus's competitive moat in inhaled RNA therapeutics.
Bears Say
Sharply Contracting RevenueA persistent, large revenue decline and deeply negative margins reflect diminished recurring income and an inability to cover fixed operating costs from core operations. Over months this increases dependence on milestone, collaboration and licensing receipts, reduces flexibility for R&D scaling, and heightens the risk that ongoing losses will erode equity if growth inflection points are delayed.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates the business cannot self‑fund growth and relies on existing liquidity or external financing. If trial timelines lengthen or manufacturing costs rise, the company may need additional capital before commercialization, potentially causing dilution or constrained investment in priority programs over the medium term.
Modality And Clinical/regulatory UncertaintyCompetitor discontinuation and a small open‑label CF study highlight structural modality risk and regulatory sensitivity for inhaled mRNA. This raises the bar for safety and efficacy evidence, complicates endpoint interpretation and enrollment, and may lengthen development timelines or require larger pivotal studies, increasing cost and execution risk over the next several quarters.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.85 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $206.92M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 34 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.01 by $0.06.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -1.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 28,423,069 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.01. Following the earnings report the stock price went up 3.596%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (125.99% Upside)
$20.00 (125.99% Upside)
Hedge Fund Trend
Increased
By 91.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
-36.55%
Trailing 12-Months
Asset Growth
-26.03%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
ARCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful clinical and regulatory progress — notably initiation of a 12‑week ARCT‑032 Phase II with tolerable repeat inhaled dosing and FDA clarity on ARCT‑810 pediatric path — supported by a strengthened leadership team and a cash runway through mid‑2028. Offsetting these positives were a material year‑over‑year revenue decline ($27.3M), a quarter‑over‑quarter cash decrease (~$19.4M, 8.3%), program‑specific manufacturing cost increases, and uncertainties tied to a small open‑label CF study and broader modality risk. On balance, the advancement of key programs and regulatory alignment outweigh the financial and operational headwinds in the near term.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$20.00
▲(125.99% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.04% Insiders
23.74% Mutual Funds
31.73% Other Institutional Investors
15.17% Public Companies and
Individual Investors